Fiche centre
Research site
Stavanger — Norway
Essais liés3clinical trials
VilleStavangerlocalisation
PaysNorwaylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06087835
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Zibotentan/Dapagliflozin | Maladie rénale chronique | Phase 3 | NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | ACTIVE_NOT_RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |
| dimethyl fumarate | SEP | Phase 4 | NCT02471560 | TECONGUT — Tecfidera and the Gut Microbiota | COMPLETED |